Navigation Links
multiforme in Medical News

European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors

... of patients with newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and ... adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as ... 65 years. In newly diagnosed glioblastoma multiforme the most common adverse reactions in clinical ...

Bradmer provides clinical trial update and announces evaluation of strategic alternatives

... will be forthcoming. About Glioblastoma multiforme Glioblastoma multiforme (GBM) is the most common and most advanced form ... to radioactive iodine, used to treat glioblastoma multiforme (GBM), the most common and most advanced form of ...

Cancer Mortality Increases With Cancer Cell Replikin Count

... mortality after 5 years.  Glioblastoma multiforme and non-small-cell lung cancer, the two cancer ... respectively).   The count in Glioblastoma multiforme is 18 times higher than the counts in prostate ... in the laboratory in the case of glioblastoma multiforme brain cancer cells in tissue culture*. The ...

Some Immature Brain Cells May Promote Tumors

... used tumor tissue from people with glioblastoma multiforme to develop a cell that ignored the effects of two ... growth. The team then analyzed 54 glioblastoma multiforme tumors and found that one in five (20 percent) ... neuronal stem-like starter cells in glioblastoma multiforme and other cancers, and give us a strong rationale ...

Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme

... kinase inhibitor, is cytotoxic to glioblastoma multiforme cell lines (Abstract No. 178). Activity was also demonstrated in vivo in a glioblastoma multiforme xenograft model. Evidence presented here ... of MP470 against glioblastoma multiforme cells is synergistic with radiation. ...

Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program

... a Phase II trial as a potential new treatment for recurrent glioblastoma multiforme (GBM), a deadly form of brain cancer. The company also reported that ... drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration. A ...

NCCN Updates Guidelines for Central Nervous System (CNS) Cancers

... to use bevacizumab as a single agent for recurrent glioblastoma multiforme in CNS cancers, the integration of a patient's Karnofsky Performance ... change in the updated NCCN Guidelines for patients with glioblastoma multiforme is the integration of a patient's Karnofsky Performance Status (KPS) score ...

Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting

... the effects of Neuradiab(TM) on Patients with Newly Diagnosed Glioblastoma multiforme (GBM). The SNO meeting is being held in Lake Las Vegas, Nevada from ... antibody, conjugated to radioactive iodine, used to treat glioblastoma multiforme (GBM), the most common and most advanced form of brain cancer. Neuradiab ...

Bradmer to present at Rodman & Renshaw Healthcare Conference

... therapy to the current standard of care for newly diagnosed glioblastoma multiforme (GBM). The presentation will take place on Wednesday, November 12th at ... antibody, conjugated to radioactive iodine, used to treat glioblastoma multiforme (GBM), the most common and most advanced form of brain cancer. Neuradiab ...

JCI online early table of contents: Aug. 1, 2008

... death improves cancer therapy efficacy Individuals with glioblastoma multiforme (GBM), one of the most aggressive types of brain tumor, have an extremely ... to individuals with GBM. TITLE: Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of ...

More>>

multiforme in Medical Technology

Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

... as a potential new treatment for glioblastoma multiforme (GBM), a deadly form of brain cancer. Cotara ... designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food ... B MAB for the treatment of recurrent glioblastoma multiforme (GBM)." Sunday, June 1, 2008 2:00 PM - 6:00 PM ...

Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme

... prolonged survival in patients with glioblastoma multiforme (GBM) versus radiation treatment alone and that a ... in favor of the TEMODAR arm. About Glioblastoma multiforme Glioblastoma multiforme is a rapidly growing tumor of the central nervous ...

Cytopia Commences Second Phase II Study in Brain Cancer

... Carboplatin and Etoposide in Relapsed Glioblastoma multiforme (CCL08001). Primary endpoints Assess safety and tolerability of ... patients. Subject selection Eligible patients must have glioblastoma multiforme criteria that has progressed after surgery, radiation ...

Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials

... two previously conducted Phase II trials of Neuradiab(TM) in glioblastoma multiforme (GBM) patients. As an exploratory endpoint of the single arm Phase II ... antibody, conjugated to radioactive iodine, used to treat glioblastoma multiforme (GBM), the most common and most advanced form of brain cancer. ...

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting

... Diagnosed Glioblastoma publication with carmustine multiforme or Anaplastic only. implant) Astrocytoma with ... Gliadel is also indicated in patients with recurrent glioblastoma multiforme as an adjunct to surgery. Gliadel should not be given to individuals who ...

Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research

... series of agents, has anti-cancer activity against human glioblastoma multiforme cells in a mouse model of cancer. Glioblastoma multiforme is the most ... brain. "We are pursuing both strategies for the treatment of glioblastoma multiforme in a rat model in which the cancer is growing in the brain," said Dr. ...

Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting

... from its ZFP Therapeutic(TM) program for the treatment of glioblastoma multiforme (GBM), a progressive and usually fatal brain cancer. The data were ... glioma-related deaths occur annually in the United States. Glioblastoma multiforme (GBM), a type of glioma, is rapidly progressive and nearly uniformly ...

Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma

... to Celldex's CDX-110 for the treatment of EGFRvIII expressing Glioblastoma multiforme (GBM). GBM is the most common and aggressive form of primary brain cancer ... particular variant, EGFRvIII occurs in about 40 percent of Glioblastoma multiforme (GBM) patients. It was discovered in a collaborative effort between Dr. ...

Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme

... Celldex's CDX-110 for the treatment of EGFRvIII expressing Glioblastoma multiforme (GBM). GBM is the most common and aggressive form of brain cancer. CDX-110 ... particular variant, EGFRvIII occurs in about 40 percent of Glioblastoma multiforme (GBM) patients. It was discovered in a collaborative effort between Dr. ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... mg/kg) for 1-2 weeks concomitantly with imatinib should be considered at the initiation of therapy. Bullous dermatologic reactions (eg, erythema multiforme and Stevens-Johnson syndrome) have also been reported. In some cases, the reaction recurred upon rechallenge. Several postmarketing reports describe ...

More>>

multiforme in Medical Dictionary

Cleft lip

... Repair - Series - Digestive System - Erythema multiforme on the Leg - Erythema multiforme , Circular Lesion s - Hands - Erythema multiforme , Target Lesion s on the Palm - Exfoliation ...

Erythema

... two weeks. Its cause is unknown. Erythema multiforme has many causes, most commonly are drugs. ... likely medication-induced causes. Erythema multiforme can also be caused by certain disease s. ... produce somewhat similar rashes . Erythema multiforme is an exaggerated allergic reaction that may be ...

Erythema multiforme

... Erythema multiforme on the hands Erythema multiforme , circular lesion s - hands Erythema multiforme , target lesion s on the palm ... ...

Erythema nodosum

... marginatum; erythema migrans; erythema multiforme ; erythema multiforme bullosum; erythema multiforme exudativum; ...

Blister

... throat, anus , genital area and eyes . A severe form of Erythema multiforme . " According to the FDA, blister packs (tablets or capsules ... experience. Blister socks really do help." Shorts ... ERYTHEMA multiforme : A skin disease characterized by popular (small, solid, usually conic ...

Erythema infectiosum

... some paleness around the mouth. Also called Fifth disease . erythema multiforme ... Parvo virus B19; Erythema infectiosum ; Slapped cheek ... help 1 ... erythema infectiosum erythema marginatum erythema multiforme erythema nodosum erythroblastosis fetalis erythrocyte ...

Conjunctivitis

... with trying to control their environment in some limited medications. STEVENS-JOHNSON SYNDROME : A severe and sometimes fatal form of erythema multiforme characterized by severe skin manifestations; conjunctivitis ( eye inflammation ), which often results in blindness ; Vincent's angina ( ...

Eyes

... reaction characterized by blister s breaking out on the lining of the mouth, throat, anus , genital area and eyes . A severe form of Erythema multiforme . Asthenopia - Term generally used to describe complaints related to refractive error, ocular muscle imbalance, including pain or aching ...

Fifth disease

... in children that begins with a red, warm rash on the face, along with some paleness around the mouth. Also called Fifth disease . erythema multiforme ... ...

Lupus nephritis

... the glomerulus and progressive loss of kidney function. Lupus Nephritis Lupus ( Systemic Lupus Erythematosus ) Lyell's Syndrome ( Erythema multiforme ) Lyme Borreliosis ( Lyme Disease - Primary ) Lyme Disease ... Initially, lupus nephritis may cause no signs or symptoms. But in some ...

More>>

multiforme in Biological News

UNC study: Scientists identify chemical compound that may stop deadly brain tumors

... gene mutation contributes to tumor growth. The findings and potential treatment apply to a type of brain tumor called secondary glioblastoma multiforme (GBM). GBMs are part of a larger group of brain tumors called malignant gliomas, which is the type of cancer Senator Edward Kennedy suffers from. ...

Salk researchers develop novel glioblastoma mouse model

... suspected to be the origin of glioblastoma. Within a few months, massive tumors that displayed all the histological characteristics of glioblastoma multiforme preferentially developed in the hippocampus and the subventricular zone. The ability of adult stem cells to divide and generate both new stem ...

Mayo Clinic Cancer Center: Harnessing the measles virus to attack cancer

... and lead researcher on the glioblastoma multiforme project in the measles virus investigation. "We ... seek out this protein, entering the glioblastoma multiforme tumor. Upon entry, the virus begins to spread, ... more potent viral doses." The glioblastoma multiforme study, which opened today, is designed to test ...

'Smart drug' targets deadly brain cancer

... categorizes fast-growing glioblastoma multiforme as a grade IV cancer. Significance of the Mayo ... percent) of patients with recurrent glioblastoma multiforme participating in this study -- which is a high ... to target specific changes in the glioblastoma multiforme tumor cells that previous studies have identified ...

Investigating the measles virus as a tool to kill multiple myeloma

... being tested today in several tumor types, including glioblastoma multiforme (a brain tumor), recurrent ovarian cancer and now multiple myeloma. ... of higher and potentially even more potent viral doses. The glioblastoma multiforme trial, which opened in the fall, is testing the safety of another strain ...

Killing brain tumors from within: A 'Trojan horse' approach

... of epidermal growth factor receptors (EGFR). This proliferation of EGFR is typical of certain types of cancer cells, including glioblastoma multiforme (GBM), the most lethal form of brain cancer. The nucleic acid-EFG molecule acts as a "guided missile," explained Prof. Levitzki, which, when ...

Scientist works to improve treatment for brain tumors

... that he developed for the most deadly type of brain tumor. Waldemar Debinski, M.D., Ph.D., pioneered a method to destroy cells of glioblastoma multiforme (GBM) with less damage to healthy cells. The drug is currently being tested in clinical trials and Debinski is working on its fourth generation in ...

Radiotherapy advance points way to noninvasive brain cancer treatment

... With an equal rate of incidence and mortality-the number of those who get it, and the number of those who die from it-Glioblastoma multiforme (GBM) is a brain cancer death sentence. Of the approximately 12,000 people who are diagnosed with GBM annually in the U.S., half will die within a ...

Preclinical study of a new brain tumor therapy

... the malignant cells. A new preclinical study, published in the open access journal PLoS Medicine, has applied the approach to combat glioblastoma multiforme (GBM). This is the most aggressive form of brain tumour, growing very quickly before symptoms are experienced and killing most patients within a year ...

More>>

multiforme in Biological Technology

SuperGen Reports 2007 Fourth Quarter and Annual Financial Results

... inhibitor, is cytotoxic to glioblastoma multiforme cell lines (Abstract 178). Activity was also demonstrated in vivo in a glioblastoma multiforme xenograft model. Evidence presented suggests that ... clinical activity of MP470 against glioblastoma multiforme cells is synergistic with radiation. ...

Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

... radioisotope being developed as a potential new treatment for glioblastoma multiforme (GBM), a deadly form of brain cancer. The results reported today from an ... drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration. A ...

Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting

... Phase II study of AT-101 as monotherapy for recurrent glioblastoma multiforme (GBM), the most aggressive form of brain cancer, were also presented(3) . ... J, et al. NABT-0702: A phase II study of AT-101 in recurrent glioblastoma multiforme (GBM). Abstract #2010; Poster Board #2; Poster Discussion, May 30, 8:00 ....

Bradmer sponsors physician panel to raise awareness of brain cancer treatments

... days on Bradmer's website. About Glioblastoma Multiforme Glioblastoma multiforme (GBM) is the most common and most advanced form of brain cancer with ... antibody, conjugated to radioactive iodine, used to treat glioblastoma multiforme (GBM), the most common and most advanced form of brain cancer. Neuradiab ...

Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008

... with HIV, and two Cotara studies for the treatment of glioblastoma multiforme (GBM), a deadly form of brain cancer. The company reported a ... a clinical update on its Cotara program for the treatment of glioblastoma multiforme (GBM), covering the first cohort of patients in its dosimetry trial as ...

Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models

... In mouse models, LB-1.2 plus Temozolomide caused complete regression without recurrence in 50 % of animals bearing tumors of human glioblastoma multiforme (GBM), the most common and aggressive brain tumor of adults, and also, marked regression of neuroblastoma, the most common cancer of children. ...

Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO

... study, which concluded in February 2009. CYT997 is currently undergoing further clinical investigation in Phase II studies in relapsed glioblastoma multiforme and multiple myeloma. Enquiries Dr. Gregg Smith Mr. Andrew Macdonald Director, Drug Development and ...

Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR

... 2009, 1:00 pm - 5:00 pm) -- Dual targeting of the receptor tyrosine kinase EGFRvIII and HGF:c-Met signaling in models of glioblastoma multiforme (GBM) Overview: Examined the effect of combining a fully human neutralizing antibody targeting the HGF:c-Met axis (AMG 102), with a ...

Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results

... when we receive the results of an ongoing 113 patient Phase 2 clinical trial of MGd combined with radiation plus temozolomide in glioblastoma multiforme (GBM). This trial is being conducted by the Radiation Therapy Oncology Group (RTOG) with results expected in late 2010." "Our management team ...

SuperGen Reports 2008 Third Quarter Financial Results

... 2008: The Company announced that the FDA granted orphan drug designation for our lead drug candidate, MP-470, for the treatment of glioblastoma multiforme (GBM), an often fatal form of brain cancer. The FDA accepted the Company's application upon review of data from in vitro studies in glioblastoma cell ...
Other Contents
(Date:7/12/2014)... injuries increase in the summer as people gather around fire ... most vulnerable to these seasonal fire hazards: children. "Young ... by putting their hands on the side of cooking grills," ... Loyola University Medical Center in Maywood, Ill., said in a ... play with fire, you get burned, is true -- ...
(Date:7/12/2014)... “After my mom’s stroke, she loss the use of her ... use of his left side. Eating became a difficult task for ... like them enjoy eating again,” said an inventor, from Fayetteville, N.C. ... HALL PLATE (P C H PLATE). , The PATRICIA CAROL HALL ... eat for individuals who suffer from stroke, experience tremors or loss ...
(Date:7/12/2014)... With prom shopping reaching its final ... is ready to showcase its new and trendy apparels. ... evening dresses in its online shop. Additionally, it is ... these elegant gowns. According to the company’s sales manager, ... 26, 2014. , He says, “Now, worldwide clients ...
(Date:7/12/2014)... “Critical Care Therapeutics in Major Developed ... PCCs and Recombinant Products to Drive Market,” which ... in the US, UK, France, Germany, Italy, Spain, ... of market size for 2013, along with market ... that are being treated using the five major ...
(Date:7/12/2014)... Utah Valley Entrepreneurial Forum Top 25 ... being bestowed to companies in revenue, and pre-revenue startups. ... with recognition for new ideas as well as companies ... , 25 Under 5 highlights outstanding Utah entrepreneurs and ... 5 years old. Award recipients were recognized at their ...
Breaking Medicine News(10 mins):Health News:Burn Injuries More Common in Summer 2Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
(Date:7/10/2014)... SPRINGS, Florida , July 1, 2014 ... wallets pave way for convenience and improved security: NXT-ID, Inc. ... Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... and MasterCard Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: NXTD) ... is pleased to announce that the second series of 30 ...
(Date:7/10/2014)... July 2, 2014 It is a great ... the appointment of the world-renowned Thoracic and Cardiovascular surgeon, ... Dr. Ginsburg, with over 34 years of ... Hospital and Good Samaritan Regional Medical Center. Dr. Ginsburg ... late 1980,s and is considered an expert in the ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
Other TagsOther Tags